Mounjaro: the facts behind the medicine everyone's asking about

The biggest myth: Mounjaro is just a stronger version of other weight-loss jabs

Most people who search for Mounjaro have already heard of semaglutide, and the shorthand that circulates is roughly: 'Mounjaro is the next one along, a bit more powerful.' That framing misses something important about how the medicine works.

Semaglutide mimics one gut hormone (GLP-1) which reduces appetite and slows the stomach's emptying rate. Tirzepatide does that too, but it also activates a second receptor: GIP (glucose-dependent insulinotropic polypeptide). These two pathways interact differently in the brain and in fat tissue, which is why clinical researchers classify tirzepatide as a dual agonist rather than simply a more potent GLP-1. The NHS medicine page for tirzepatide describes this dual mechanism clearly and is worth reading before any consultation.

In practice, the difference shows up in the trial data. The SURMOUNT-1 study randomised 2,539 adults with obesity over 72 weeks; average weight reduction at the 15 mg dose reached around 20–21%. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same period, and if you are curious how it compares with similar products in the tirzepatide class, that page sets out the landscape clearly. Greater effect does not mean better fit for every individual, which is exactly what a prescriber is there to work out.

So: a more powerful mechanism, yes. An identical one dialled up, no.

Who Mounjaro is actually licensed for, and what that means in practice

The licensed indication covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or osteoarthritis. Lower BMI thresholds can apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK clinical guidance.

NICE recommended tirzepatide in December 2024 (TA1026) for NHS use in adults with a BMI of at least 35 plus one or more weight-related conditions, with phased criteria for NHS commissioning, a narrow window compared with the private licensed threshold. For people considering private treatment, the licensed eligibility is broader, but it still requires a prescriber to assess the full clinical picture. BMI alone never settles the question. History of pancreatitis, certain thyroid conditions, pregnancy, breastfeeding or trying to conceive all affect suitability; those circumstances need an open conversation with a clinician, not a checkbox.

Under-18s: not licensed. The position on pregnancy and conception is clear, not recommended, and a wash-out period applies before trying to conceive.

The treatment schedule and what the first few weeks actually feel like

Tirzepatide comes as a pre-filled KwikPen. Each pen contains four weekly doses administered as a subcutaneous injection, into the abdomen, thigh or upper arm, rotating the site. The starting dose is 2.5 mg; its job is to help the body adjust to the medicine, not to drive weight loss. Prescribers typically increase the dose in four-week steps based on tolerability, working toward a maintenance level that suits each person.

The most commonly reported side effects in the early weeks are gastrointestinal: nausea, loose stools, indigestion, a sense of fullness. These tend to ease as the body adapts, and they are one reason the titration schedule exists. Serious side effects are less common but real: acute pancreatitis in particular, the MHRA issued guidance on this in January 2026, advising anyone experiencing severe, persistent stomach pain that radiates to the back to seek urgent medical help. A full side-effect profile is set out in the Mounjaro SmPC on the eMC and in the patient information leaflet included with the pen.

Storage is in the fridge at 2–8°C. The exact window for keeping the pen at room temperature (useful when travelling) is specified in the leaflet, and that is the right place to check rather than a general article. More on Mounjaro pen formats is available if you want to understand what you are injecting before you start.

Mounjaro, cost and what a legitimate private route looks like

It is worth being direct about price, because the range reported across private providers is wide. Eli Lilly raised Mounjaro's UK list price significantly from September 2025; since then, typical private monthly costs have been reported at roughly £149–£375 depending on dose and provider, and our Mounjaro introductory offer is worth checking if you are weighing up the cost of getting started. Those figures are market context, not a promise from any single service.

A fuller breakdown of what drives the variation (consultation fees, prescription fees, aftercare, whether dose reviews are included) is on our Mounjaro cost page. The short version: a headline price that excludes clinical oversight is not cheaper treatment, it is less treatment. For a prescription medicine with a titration schedule and a side-effect profile, the clinical wrap matters.

Anyone considering Mounjaro through an online pharmacy should verify it on the GPhC pharmacy register before sharing any personal information. Counterfeit pens are a documented MHRA concern; sellers offering these medicines without a valid prescription are a red flag, not a bargain. Our FAQs cover what to look for when assessing any provider.

If Mounjaro sounds right for you, the next step is a conversation. You can also read more about who produces Mounjaro and the company behind it if you want to understand the manufacturer before proceeding. Speak to our prescribers through a free consultation and they will assess whether it is clinically appropriate, start that conversation here.